Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 ...

The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735. Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7 ...

Many investors may have been hoping that another, larger healthcare company would acquire it for its promising GLP-1 treatment, VK2735 -- but that doesn't appear to be happening. And with a ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose ...

In the second quarter of 2025, the business intends to start Phase 3 studies for their subcutaneous obesity therapy, VK2735. Targeting metabolic and endocrine diseases, the San Diego-based ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy. VK2735 is a dual GLP-1/GIP medicine, the same class as Eli Lilly's Zepbound.

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 ...

As a matter of fact, it is developing dual GLP-1/GIP agonist VK2735 both as an injectable and oral drug for the treatment of obesity. It anticipates beginning a Phase 2 study for oral VK2735 ...

"During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of ...